Michael Millward - Concepedia

Author

Michael Millward

The University of Western Australia ORCID

Also Known As

M J Millward, M Millward, M. J. MILLWARD, M. J. Millward, M. Millward, M.J Millward, M.J. Millward, MICHAEL J. MILLWARD, Michael J MILLWARD, Michael J Millward

454

Publications

15.8K

Citations

H-Index

140

Concepts

All Affiliations

The University of Western Australia Sir Charles Gairdner Hospital Peter MacCallum Cancer Centre The University of Sydney Edith Cowan University

About

Michael Millward is an author at The University of Western Australia specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	37	95	7.1K
2	Health Sciences	15	17	642
3	Engineering	4	4	198
4	Natural Sciences	1	1	15
5	Nursing	1	1	26

Michael Millward

189

Publications

14.7K

Citations

H-Index

Page 1

	Year	Citations
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, New England Journal of Medicine	2014	1.8K
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, The Lancet Versus DabrafenibVal600 Braf-mutant MelanomaOncologyMelanomaPharmacotherapy	2015	1.4K
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, The Lancet Neuro-oncologyUntreated Brain MetastasesMedicineMelanomaPharmacotherapy	2012	928
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study Georgina V. Long, Keith T. Flaherty, Daniil Stroyakovskiy, Annals of Oncology	2017	640
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, The Lancet Oncology Checkmate 238Surgical OncologyMedicineMelanomaPathology	2020	505
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor Kevin B. Kim, Richard Kefford, Anna C. Pavlick, Journal of Clinical Oncology	2012	473
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma Elin S. Gray, Helen Rizos, Anna Reid, Oncotarget Baseline Ctdna LevelsImmunologyPathologyNucleic Acid BiomarkersTumor Biology	2015	322
Phase III Study of Adjuvant Vaccination With Bec2/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study) Giuseppe Giaccone, C. Debruyne, Enriqueta Felip, Journal of Clinical Oncology	2005	220
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment Rachael M. Zemek, Emma de Jong, Wee Loong Chin, Science Translational Medicine	2019	210
Fatal pulmonary toxicity resulting from treatment with gemcitabine Nick Pavlakis, David Bell, Michael Millward, Cancer	1997	192

Page 1